©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2014; 20(1): 118-125
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.118
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.118
Table 2 New tissue and serum tumor markers for specific diagnostics and prognostics of gastric neuroendocrine tumors
| Ref. | Case | Hormones, amines and peptides for specific diagnostic and prognostics of GNETs | Expression |
| Giandomenico et al[42] | 15 | CD133 | 20% positive |
| Mia-Jan et al[43] | 2 | ISL1 | Complete loss |
| Agaimy et al[44] | 1 | c-kit | Overexpression |
| Mori et al[45] | 51 | Cyclin E | Independent prognostic factor |
| Cyclin E and P53 | Prognostic relevance | ||
| Namikawa et al[41] | 5 | Chromogranin A | 40% positive |
| Synaptophysin | 60% positive | ||
| CD56 | 60% positive | ||
| Neuron-specific enolase | 40% positive | ||
| p53 protein | 100% positive |
- Citation: Li TT, Qiu F, Qian ZR, Wan J, Qi XK, Wu BY. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol 2014; 20(1): 118-125
- URL: https://www.wjgnet.com/1007-9327/full/v20/i1/118.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i1.118